“The right target, at the right time, for the right price” …is and always has been a guiding principle for Merck KGaA, as stated by its CEO, Belen Garijo. It appears that Merck KGaA has now identified the ‘right’ acquisition target - SpringWorks Therapeutics. As reported by Reuters, Merck KGaA is in advanced talks to acquire the US-based cancer and rare disease biotech SpringWorks. The potential deal, which could be finalized in the coming weeks, is expected to expand Merck’